Long-term survivors in glioblastoma patients homogeneously treated with the Stupp regimen, clinical characteristics and MGMT status: Initial results from the GLIOCAT study.

e13513Background: Prognosis of GBM pts is still poor with a median survival of 15 months; however a small fraction survives more than 30 months, defined in our study as long term survivors (LTS-30) Methods: We performed a multicenter retrospective and prospective study of newly GBM pts treated homogeneously with the Stupp Regimen. In the present sub-study we analyze clinical characteristics and MGMT status in LTS-30 compared with pts surviving less than 30 months. Data from IDH1 mutation will be available for ASCO meeting. Results: From 2005 to 2014, 432 GBM pts homogeneously treated with the Stuup Regimen were included with a median progression free survival (PFS) of 8 months and a median overall survival of 15 months, of which 41 (9.5%) were long term survivors LTS-30, with a median PFS of 17 months and a median OS of 38 months. In this population median karnofsky index (KPS) was better (90% versus 80%) with less patients with KPS inferior to 80% (6% versus 41%; p=0.004), and median age was also younger...